- Home
- BIRD vs LIVN Comparison
BIRD vs LIVN Comparison
Compare BIRD & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- LIVN
- Stock Information
- Founded
- BIRD 2015
- LIVN 1987
- Country
- BIRD United States
- LIVN United Kingdom
- Employees
- BIRD N/A
- LIVN N/A
- Industry
- BIRD Apparel
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BIRD Consumer Discretionary
- LIVN Health Care
- Exchange
- BIRD Nasdaq
- LIVN Nasdaq
- Market Cap
- BIRD 55.3M
- LIVN 2.8B
- IPO Year
- BIRD 2021
- LIVN 1993
- Fundamental
- Price
- BIRD $6.49
- LIVN $47.63
- Analyst Decision
- BIRD Hold
- LIVN Buy
- Analyst Count
- BIRD 3
- LIVN 7
- Target Price
- BIRD $18.00
- LIVN $67.14
- AVG Volume (30 Days)
- BIRD 68.9K
- LIVN 513.2K
- Earning Date
- BIRD 11-06-2024
- LIVN 02-19-2025
- Dividend Yield
- BIRD N/A
- LIVN N/A
- EPS Growth
- BIRD N/A
- LIVN 759.09
- EPS
- BIRD N/A
- LIVN 0.43
- Revenue
- BIRD $205,895,000.00
- LIVN $1,241,739,000.00
- Revenue This Year
- BIRD N/A
- LIVN $10.10
- Revenue Next Year
- BIRD N/A
- LIVN $5.43
- P/E Ratio
- BIRD N/A
- LIVN $110.48
- Revenue Growth
- BIRD N/A
- LIVN 11.04
- 52 Week Low
- BIRD $6.11
- LIVN $43.15
- 52 Week High
- BIRD $22.40
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- BIRD 34.63
- LIVN 46.19
- Support Level
- BIRD $6.11
- LIVN $46.02
- Resistance Level
- BIRD $7.60
- LIVN $48.13
- Average True Range (ATR)
- BIRD 0.46
- LIVN 1.12
- MACD
- BIRD -0.01
- LIVN 0.19
- Stochastic Oscillator
- BIRD 25.57
- LIVN 78.00
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.